A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting

Basit Öğe Kaydı
dc.contributor.authorCesur, Mustafa
dc.contributor.authorCorapcioglu, Demet
dc.contributor.authorGursoy, Alptekin
dc.contributor.authorGonen, Sait
dc.contributor.authorOzduman, Mine
dc.contributor.authorEmral, Rifat
dc.contributor.authorUysal, Ali Riza
dc.date.accessioned2020-03-26T17:16:55Z
dc.date.available2020-03-26T17:16:55Z
dc.date.issued2007
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAlthough diabetics may be exempted from Ramadan fasting, many patients still insist on this worship. Aim of the present study is to compare the effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetics during Ramadan fasting on the glucose metabolism. Patients, who were willing to fast, were treated with glimepiride (n = 21), repaglinide (n = 18), and insulin glargine (n = 10). Sixteen non-fasting control type 2 diabetics matched for age, sex, and body mass index were also included. Fasting blood glucose (FBG), post-prandial blood glucose (PBG), HbA1c, and fructosamine as well as lipid metabolism were evaluated in pre-Ramadan, post-Ramadan, and I-month post-Ramadan time points. There was no significant change from pre-Ramadan in FBG, PBG, and HbA1c variables in fasting diabetics at post-Ramadan and 1-month post-Ramadan. However, PBG was found higher in non-fasting control diabetics at post-Ramadan and 1-month post-Ramadan (p < 0.05 and p < 0.001, respectively). In fructosamine levels, a significant increase was noted both in fasting group and non-fasting group at 1-month post-Ramadan (p < 0.01 for all). However, no significant difference was found in the comparison of the changes in fructosamine levels between fasting group and non-fasting group. Risk of hypoglycemia did not significantly differ between fasting and non-fasting diabetics. There was no significant difference between three drug therapies regarding glucose metabolism and rate of hypoglycemia. No adverse effects on plasma lipids were noted in fasting diabetics. In this fasting sample of patients with type 2 diabetes, glimepiride, repaglinide, and insulin glargine did not produce significant changes in glucose and lipid parameters. (c) 2006 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.diabres.2006.05.012en_US
dc.identifier.endpage147en_US
dc.identifier.issn0168-8227en_US
dc.identifier.issn1872-8227en_US
dc.identifier.issue2en_US
dc.identifier.pmid16815586en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage141en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.diabres.2006.05.012
dc.identifier.urihttps://hdl.handle.net/20.500.12395/21165
dc.identifier.volume75en_US
dc.identifier.wosWOS:000243668600003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherELSEVIER IRELAND LTDen_US
dc.relation.ispartofDIABETES RESEARCH AND CLINICAL PRACTICEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjecttype 2 diabetesen_US
dc.subjectRamadanen_US
dc.subjectfastingen_US
dc.subjectglimepirideen_US
dc.subjectrepaglanideen_US
dc.subjectinsulin glargineen_US
dc.subjectglucose parametersen_US
dc.subjectlipid parametersen_US
dc.titleA comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fastingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu